Cargando…
Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report
The emergence of immune checkpoint inhibitors (ICIs) in recent years has transformed the landscape of the management of solid tumors. The advancement of immunotherapy has resulted in a brand new set of adverse outcomes not previously seen in classical chemotherapy. One such adverse effect has been t...
Autores principales: | Chan, Kok Hoe, Lakkasani, Saraswathi, Ramahi, Amr, Shaaban, Hamid S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243062/ https://www.ncbi.nlm.nih.gov/pubmed/32455081 http://dx.doi.org/10.7759/cureus.7764 |
Ejemplares similares
-
Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020) -
Cryoglobulinemia unmasked by nivolumab in a patient with hepatitis C-induced hepatocellular carcinoma: A case report and literature review
por: Ramahi, Amr, et al.
Publicado: (2021) -
Diffuse bone metastasis from cholangiocarcinoma involving the sternum: A case report and review of literature
por: Singh, Balraj, et al.
Publicado: (2021) -
Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature
por: Kazemi, Nazanin Yeganeh, et al.
Publicado: (2022) -
Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study
por: Tanaka, Yuko, et al.
Publicado: (2019)